sever
virus
caus
pulmonari
infect
due
share
tropism
cell
respiratori
tract
respiratori
problem
due
viral
infect
becom
public
health
concern
due
rapid
transmiss
airaerosol
via
directindirect
contact
infect
person
addit
crossspeci
transmiss
caus
alter
viral
genet
makeup
therebi
increas
risk
emerg
pathogen
new
potent
infect
introduct
effect
nucleic
acidbas
technolog
post
translat
gene
silenc
ptg
increasingli
use
silenc
viral
gene
target
shown
promis
approach
toward
manag
mani
viral
infect
sinc
sever
host
factor
also
util
virus
variou
stage
infect
silenc
host
factor
also
serv
promis
therapeut
tool
sever
nucleic
acidbas
technolog
short
interf
rna
sirna
antisens
oligonucleotid
aptam
deoxyribozym
dnazym
ribozym
studi
use
manag
respiratori
virus
therapeut
nucleic
acid
effici
deliv
airway
studi
also
shown
efficaci
gene
therapi
clinic
trial
respiratori
syncyti
viru
rsv
well
model
respiratori
diseas
includ
sever
acut
respiratori
syndrom
sar
measl
influenza
review
summar
recent
advanc
made
area
nucleic
acid
base
therapeut
highlight
emerg
role
nucleic
acid
manag
sever
respiratori
viral
infect
also
focus
method
deliveri
associ
challeng
mani
virus
show
tropism
cell
respiratori
tract
support
viral
entri
subsequ
infect
infect
respiratori
virus
often
lead
season
epidem
case
threaten
pandem
case
signific
morbid
mortal
respiratori
virus
gener
spread
rapidli
due
mode
transmiss
simpl
inhal
droplet
contain
viral
particl
physic
contact
contamin
item
spread
dicer
bind
doublestrand
rna
dsrna
cleav
short
piec
nt
call
sirna
one
strand
rna
associ
rna
induc
silenc
complex
risc
protein
bind
target
mrna
mrna
cleav
nucleas
activ
risc
long
dsrna
introduc
cell
directli
via
viru
transposon
immedi
recogn
rna
bind
domain
rbd
enzym
dicer
contain
endonucleas
catalyt
domain
dsrna
get
cleav
short
sirna
molecul
get
bound
multiprotein
compon
complex
refer
risc
rna
induc
silenc
complex
one
sirna
strand
guid
align
risc
complex
target
mrna
thereaft
dicer
recruit
argonaut
protein
also
rnase
slice
target
mrna
thu
caus
gene
suppress
consequ
decreas
protein
level
figur
highli
specif
cleav
abil
sirna
make
potent
prophylact
therapeut
treatment
option
target
diseasecaus
gene
howev
optim
requir
sirna
design
avoid
offtarget
effect
minim
possibl
side
effect
host
cell
presenc
doubl
strand
rna
consequ
viral
infect
trigger
rna
interfer
rnai
host
enzym
dicer
bind
doublestrand
rna
dsrna
cleav
short
piec
nt
call
sirna
one
strand
rna
associ
rna
induc
silenc
complex
risc
protein
bind
target
mrna
mrna
cleav
nucleas
activ
risc
long
dsrna
introduc
cell
directli
via
viru
transposon
immedi
recogn
rna
bind
domain
rbd
enzym
dicer
contain
endonucleas
catalyt
domain
dsrna
get
cleav
short
sirna
molecul
get
bound
multiprotein
compon
complex
refer
risc
rna
induc
silenc
complex
one
sirna
strand
guid
align
risc
complex
target
mrna
thereaft
dicer
recruit
argonaut
protein
also
rnase
slice
target
mrna
thu
caus
gene
suppress
consequ
decreas
protein
level
figur
highli
specif
cleav
abil
sirna
make
potent
prophylact
therapeut
treatment
option
target
diseasecaus
gene
howev
optim
requir
sirna
design
avoid
offtarget
effect
minim
possibl
side
effect
host
cell
bacteria
virus
caus
respiratori
infect
airway
antimicrobi
resist
made
treatment
difficult
mani
infecti
diseas
includ
respiratori
infect
rnai
therapeut
proven
effect
infect
sinc
rnai
therapi
target
rna
advantag
convent
small
molecul
drug
use
therapi
respiratori
diseas
sinc
first
time
rnai
use
p
f
sequenc
respiratori
syncyti
viru
rsv
increas
number
studi
relat
potenti
rnai
technolog
treatment
respiratori
viral
infect
includ
influenza
sever
acut
respiratori
syndrom
sar
rnai
molecul
design
specif
target
specif
sequenc
viral
mrna
thu
also
use
effici
mutat
viral
strain
compar
antivir
drug
season
influenza
virus
one
foremost
public
health
concern
especi
influenza
type
virus
associ
annual
epidem
worldwid
recent
pandem
caus
high
morbid
mortal
remind
influenza
virus
highli
unpredict
continu
effort
need
manag
pandem
scenario
short
time
antivir
drug
current
approv
treat
influenza
includ
adamantan
ionchannel
protein
inhibitor
neuraminidas
inhibitor
zanamivir
oseltamivir
viral
strain
found
resist
drug
thu
emphas
need
urgent
develop
new
antivir
drug
though
viru
sometim
inhibit
effect
host
gene
silenc
studi
use
synthet
sirna
due
import
viral
replic
progress
commonli
target
viral
region
nucleocapsid
protein
np
polymeras
basic
protein
polymeras
acid
protein
pa
highli
conserv
across
differ
subtyp
influenza
viru
strain
first
anim
studi
use
rnai
influenza
describ
author
show
target
mrna
degrad
use
npand
paspecif
sirna
result
global
inhibit
viral
rna
transcript
reason
signific
inhibit
newli
synthes
np
pa
protein
indispens
influenza
viral
strain
anoth
studi
polyethyleneimin
pei
complex
contain
sirna
np
pa
administ
intraven
mice
either
hour
h
h
influenza
viru
strain
infect
combin
sirna
enhanc
antivir
effect
studi
also
indic
rnai
mediat
sirna
could
partial
control
influenza
viru
even
administ
viral
infect
mice
studi
also
emphas
long
last
effect
short
hairpin
rna
np
pb
shrna
express
dna
vector
observ
suggest
sirna
coupl
appropri
carrier
optim
formul
may
provid
basi
prevent
treatment
influenza
viru
administr
sirna
use
lipid
carrier
influenzainfect
mice
hydrodynam
inject
intranas
effici
save
anim
highli
pathogen
avian
influenza
virus
iav
subtyp
studi
also
target
gene
influenza
viru
demonstr
signific
decreas
viral
replic
experiment
mice
followup
studi
group
gene
influenza
viru
target
use
sirnarz
chimer
construct
lead
consider
decreas
viru
titer
experiment
condit
grow
number
studi
search
potenti
usag
sirna
vivo
vitro
model
treatment
influenza
although
setback
usag
therapi
due
innat
immun
respons
rather
rnai
mediat
viral
inhibit
advanc
chemic
modifi
rnai
molecul
potenti
trigger
less
immun
respons
could
help
address
concern
studi
also
carri
sirna
mediat
knockdown
cellular
protein
author
target
ranbind
protein
result
delay
accrual
viral
rna
polymeras
complex
infect
cell
therebi
confirm
cellular
gene
along
viral
gene
also
target
therapeut
intervent
viral
diseas
rsv
infect
one
lead
caus
respiratori
distress
children
adult
infect
lead
selflimit
upper
respiratori
ill
howev
prematur
infant
immunocompromis
patient
especi
heart
lung
diseas
sever
rsv
infect
current
treatment
plan
rsv
limit
benefit
includ
bronchodil
corticosteroid
antibiot
bacteri
coinfect
date
unavail
licens
vaccin
avail
rsv
thu
present
urgent
need
develop
effect
rsv
therapeut
vaccin
protect
pediatr
adult
popul
sinc
rsv
replic
take
place
respiratori
epithelium
nasal
deliveri
rnai
molecul
help
inhibit
rsv
replic
studi
year
sirna
viral
phosphoprotein
p
protein
given
intranas
mice
without
help
transfect
agent
prove
effect
rsv
parainfluenza
viru
piv
antivir
activ
sirna
anim
model
compar
cell
cultur
experi
also
reveal
competit
rnai
machineri
sirna
two
differ
virus
use
dual
infect
set
observ
excess
one
sirna
tone
inhibitori
effect
studi
also
suggest
properli
design
low
dosag
inhal
sirna
might
prove
effect
antivir
treatment
respiratori
viral
infect
human
compar
complex
sirna
nake
sirna
show
approxim
effici
moreov
studi
also
reveal
administr
sirna
rsv
infect
effect
treatment
infect
sinc
sirna
p
protein
could
target
viral
strain
anoth
sirna
could
target
viral
nucleocapsid
protein
n
protein
design
usag
sirna
develop
alnylam
pharmaceut
decreas
viral
load
significantli
anim
model
also
phase
clinic
studi
prove
success
less
side
effect
phase
ii
trial
also
success
given
healthi
adult
form
nasal
spray
daili
two
day
prior
three
day
rsv
infect
result
show
compar
placebo
group
subject
treat
significantli
lower
number
rsv
infect
show
antivir
efficaci
reduc
acquisit
viral
infect
observ
within
day
viru
inocul
continu
till
end
studi
also
enter
phase
ii
b
clinic
trial
rsvinfect
lung
transplant
patient
though
margin
report
decreas
new
progress
bronchiol
obliteran
syndrom
bo
patient
statist
nonsignific
still
promis
futurist
associ
signific
advers
event
adult
popul
howev
safeti
efficaci
drug
yet
disclos
highli
suscept
pediatr
popul
sinc
usag
sirna
target
cellular
protein
requir
influenza
viru
show
signific
result
approach
appli
case
rsv
howev
kept
mind
cellular
genesprotein
indispens
cell
surviv
among
protein
actin
regulatori
protein
vasp
vasodilatorstimul
phosphoprotein
zyxin
thu
sirna
protein
use
rsv
protein
nonessenti
cell
surviv
requir
maintain
normal
physiolog
condit
henc
short
exposur
specif
sirna
afford
critic
condit
sarscov
anoth
major
caus
respiratori
distress
good
vaccin
effect
treatment
sarscov
infect
reli
rnai
therapi
counter
infect
may
prove
import
tool
counter
infect
detail
descript
sarscov
genom
allow
immedi
advanc
sarscov
rnai
base
therapeut
clinic
trial
underway
success
achiev
cell
cultur
model
identif
candid
nucleic
acid
pave
path
ration
design
sirna
viral
segment
wang
et
al
gener
six
antivir
rnai
activ
target
variou
specif
site
within
sarscov
genom
similar
antivir
effect
orf
sequenc
studi
use
vero
cell
cultur
anim
model
rnai
activ
decreas
viral
replic
weaken
cytopath
effect
demonstr
high
efficaci
design
synthet
sirna
viru
inhibitori
effect
sirna
design
sequenc
remark
recent
effect
synthet
sirna
cognat
orf
region
sarscov
genom
also
investig
murin
rhesu
macaqu
model
otherwis
unmodifi
short
duplex
dtdt
overhang
end
intranas
administr
dextros
solubl
sirna
sarscovinfect
cell
inhibit
replic
sarscov
effect
anoth
studi
sirna
specif
protein
respons
viral
entri
glycoprotein
show
signific
inhibit
viral
replic
virusinfect
cell
adenovirus
also
known
caus
mild
respiratori
gastrointestin
infect
sever
studi
util
sirna
adenoviru
inhibit
replic
one
studi
author
design
sever
sirna
earli
late
hexon
gene
adenoviru
show
variabl
degre
inhibit
viru
replic
studi
also
reveal
silenc
late
gene
effici
silenc
earli
gene
obstruct
viru
replic
ribozym
rna
molecul
catalyt
activ
like
dnazym
sinc
discoveri
role
rna
catalysi
shown
sever
biolog
process
rna
splice
rna
process
replic
rna
genom
rz
occur
natur
mainli
cleav
phosphodiest
bond
nucleic
acid
sever
class
ribozym
hammerhead
hairpin
ribozym
receiv
great
deal
attent
smaller
size
hammerhead
rz
conserv
catalyt
core
target
rna
nux
nani
nucleotid
xani
nucleotid
except
guanosin
sequenc
along
two
flank
hybrid
arm
complimentari
target
rna
figur
sever
studi
util
hammerhead
rz
catalyt
cleav
target
rna
due
high
catalyt
activ
hammerhead
hairpin
ribozym
differ
studi
use
significantli
disrupt
reduc
viral
replic
henc
effect
inhibit
pregenom
rna
level
infect
virus
dextros
solubl
sirna
sarscovinfect
cell
inhibit
replic
sarscov
effect
anoth
studi
sirna
specif
protein
respons
viral
entri
glycoprotein
show
signific
inhibit
viral
replic
virusinfect
cell
adenovirus
also
known
caus
mild
respiratori
gastrointestin
infect
sever
studi
util
sirna
adenoviru
inhibit
replic
one
studi
author
design
sever
sirna
earli
late
hexon
gene
adenoviru
show
variabl
degre
inhibit
viru
replic
studi
also
reveal
silenc
late
gene
effici
silenc
earli
gene
obstruct
viru
replic
ribozym
rna
molecul
catalyt
activ
like
dnazym
sinc
discoveri
role
rna
catalysi
shown
sever
biolog
process
rna
splice
rna
process
replic
rna
genom
rz
occur
natur
mainli
cleav
phosphodiest
bond
nucleic
acid
sever
class
ribozym
hammerhead
hairpin
ribozym
receiv
great
deal
attent
smaller
size
hammerhead
rz
conserv
catalyt
core
target
rna
nux
nani
nucleotid
xani
nucleotid
except
guanosin
sequenc
along
two
flank
hybrid
arm
complimentari
target
rna
figur
sever
studi
util
hammerhead
rz
catalyt
cleav
target
rna
due
high
catalyt
activ
hammerhead
hairpin
ribozym
differ
studi
use
significantli
disrupt
reduc
viral
replic
henc
effect
inhibit
pregenom
rna
level
infect
virus
ribozym
bind
target
mrna
make
mrnaribozym
complex
catalyt
motif
ribozym
cleav
target
rna
piec
thu
inhibit
gene
express
cleav
rna
target
ribozym
becom
free
enter
next
cycl
ribozym
bind
target
mrna
make
mrnaribozym
complex
catalyt
motif
ribozym
cleav
target
rna
piec
thu
inhibit
gene
express
cleav
rna
target
ribozym
becom
free
enter
next
cycl
propens
high
mutat
rna
virus
lead
emerg
drug
resist
strain
major
challeng
antivir
chemotherapi
overcom
toxic
resist
concern
natur
occur
molecul
ribozym
host
cell
extens
explor
potenti
therapeut
agent
tang
et
al
studi
show
ribozym
mediat
inhibit
influenza
viru
infect
vitro
vivo
experi
design
hammerhead
hairpin
ribozym
cleav
viral
rnaseg
influenza
viru
observ
effect
hammerhead
rz
better
hairpin
rz
anoth
studi
motard
et
al
sofahdvribozym
engin
therapeut
agent
recogn
conserv
region
influenza
viru
sequenc
catalyt
cleav
correspond
viral
mrna
target
disrupt
viral
replic
character
ribozym
antivir
effect
cell
cultur
mice
support
prophylact
potenti
sofahdvribozym
combin
influenza
antiinfect
serv
novel
strategi
antivir
genet
highli
variabl
respiratori
virus
studi
also
show
util
extern
guid
sequenc
eg
ribonucleas
p
type
ribozym
inhibit
influenza
viru
product
mous
cell
yet
anoth
studi
influenza
viru
gene
target
rz
direct
cleav
mrna
target
cell
made
express
design
rz
effect
inhibit
influenza
viru
strain
product
subsequ
virusspecif
protein
synthesi
evalu
studi
show
signific
inhibit
viru
reproduct
design
rz
compar
control
cell
anoth
novel
mechanist
studi
author
design
sirnachimericribozym
construct
inhibit
influenza
viru
replic
design
sirna
hammerhead
rz
direct
cleav
rna
influenza
viru
chimer
construct
demonstr
protect
viru
challeng
howev
select
disabl
mutant
construct
far
less
effect
anoth
followup
studi
group
show
effect
sever
rz
design
target
multipl
site
mrna
influenza
viru
studi
demonstr
use
togeth
gave
enhanc
cleavag
effect
use
individu
addit
effect
studi
also
show
antisens
molecul
design
hybrid
specif
sequenc
upstream
downstream
gave
signific
cleavag
effect
alon
ribozym
also
reportedli
use
gener
recombin
influenza
virus
studi
dealt
transfect
plasmid
carri
human
rna
polymeras
promot
hepat
delta
viru
ribozym
sequenc
vero
cell
order
rescu
influenza
virus
revers
genet
studi
perform
sarscoronaviru
use
chimer
dnarna
hammerhead
ribozym
show
use
rz
inhibit
viru
replic
upto
author
show
chimer
construct
target
sarscov
significantli
reduc
express
sarscov
rna
cell
transfect
recombin
plasmid
thu
prove
feasibl
treatment
option
sar
viru
infect
target
cell
begin
step
success
entri
follow
traffick
cytosol
viral
genom
reach
destin
event
specif
viral
protein
interact
sever
host
protein
order
initi
signal
requir
infect
one
studi
focus
identif
optim
rz
target
site
within
fusion
gene
adenoviru
kda
protein
suggest
rz
mechan
also
exploit
studi
function
host
protein
requir
viral
infect
dna
first
isol
year
ago
identifi
jame
watson
franci
crick
year
ago
initi
function
attribut
dna
carri
pass
genet
inform
one
gener
anoth
howev
advanc
scienc
dna
molecul
got
recognit
new
role
field
materi
scienc
deoxyribozym
also
known
dnazym
dna
enzym
synthet
catalyt
singlestrand
deoxyribonucl
acid
molecul
display
precis
substrat
recognit
abil
cleav
sequencespecif
mrna
molecul
greater
biolog
stabil
dz
molecul
one
central
catalyt
motif
flank
two
arm
arm
ii
design
complimentari
target
rna
molecul
design
dz
bind
watsoncrick
basi
figur
sever
type
dnazym
known
catalyz
function
like
rna
ligat
carboncarbon
bond
format
hydrolyt
cleavag
dna
best
character
one
still
rnacleav
dnazym
dnazym
report
occur
natur
dna
molecul
predominantli
doubl
strand
howev
breaker
joyc
gener
dnazym
de
novo
vitro
select
process
year
vitro
select
experi
gener
two
prototyp
denot
rnacleav
dna
enzym
dz
studi
sever
research
shown
cleav
target
rna
purin
pyrimidin
vivo
vitro
condit
dz
also
cleav
rna
howev
less
popular
less
establish
efficaci
dz
cleav
g
nucleotid
requir
rgdt
wobbl
pair
enzymesubstr
complex
locat
immedi
cleavag
site
cleavag
activ
deoxyribozym
also
known
dnazym
dna
enzym
synthet
catalyt
singlestrand
deoxyribonucl
acid
molecul
display
precis
substrat
recognit
abil
cleav
sequencespecif
mrna
molecul
greater
biolog
stabil
dz
molecul
one
central
catalyt
motif
flank
two
arm
arm
ii
design
complimentari
target
rna
molecul
design
dz
bind
watsoncrick
basi
figur
sever
type
dnazym
known
catalyz
function
like
rna
ligat
carboncarbon
bond
format
hydrolyt
cleavag
dna
best
character
one
still
rnacleav
dnazym
dnazym
report
occur
natur
dna
molecul
predominantli
doubl
strand
howev
breaker
joyc
gener
dnazym
de
novo
vitro
select
process
year
vitro
select
experi
gener
two
prototyp
denot
rnacleav
dna
enzym
dz
studi
sever
research
shown
cleav
target
rna
purin
pyrimidin
vivo
vitro
condit
dz
also
cleav
rna
howev
less
popular
less
establish
efficaci
dz
cleav
g
nucleotid
requir
rgdt
wobbl
pair
enzymesubstr
complex
locat
immedi
cleavag
site
cleavag
activ
dnazym
bind
target
mrna
make
mrnadnazym
complex
catalyt
motif
dnazym
cleav
target
rna
piec
thu
inhibit
gene
express
cleav
rna
target
dnazym
becom
free
enter
next
cycl
dnabas
drug
notabl
advantag
current
avail
low
molecular
weight
pharmaceut
specif
recognit
molecular
target
result
pinpoint
action
sever
studi
demonstr
effect
dnazym
specif
target
vital
gene
influenza
viru
rsv
sarscov
inhibit
replic
cell
line
mice
model
toyoda
et
al
investig
use
dz
target
mrna
inhibit
viru
replic
potenti
therapeut
respiratori
infect
caus
influenza
viru
dz
especi
longer
substratebind
domain
abl
inhibit
influenza
viru
dnabas
drug
notabl
advantag
current
avail
low
molecular
weight
pharmaceut
specif
recognit
molecular
target
result
pinpoint
action
sever
studi
demonstr
effect
dnazym
specif
target
vital
gene
influenza
viru
rsv
sarscov
inhibit
replic
cell
line
mice
model
toyoda
et
al
investig
use
dz
target
mrna
inhibit
viru
replic
potenti
therapeut
respiratori
infect
caus
influenza
viru
dz
especi
longer
substratebind
domain
abl
inhibit
influenza
viru
replic
cell
modifi
dz
similarli
shown
inhibit
influenza
viru
activ
analogu
contain
phosphoramid
linkag
reduc
level
influenza
viru
replic
demonstr
activ
toward
influenza
b
viru
likewis
catalyt
inact
mutant
show
inhibit
perhap
due
antisens
action
sever
novel
dz
hammerhead
ribozym
rz
construct
cleav
conserv
domain
influenza
viru
rna
antivir
strategi
reduc
infecti
viru
realtim
polymeras
chain
reaction
pcr
studi
show
dz
rz
inhibit
replic
viru
individu
substanti
decreas
viru
replic
use
simultan
author
conclud
combin
catalyt
dz
rz
antisens
molecul
lead
effici
gene
suppress
complet
inhibit
viru
replic
host
cell
variou
dz
also
studi
activ
influenza
b
viru
target
ion
channel
protein
highli
conserv
sequenc
crucial
uncoat
process
influenza
viru
one
dz
demonstr
signific
intracellular
reduct
gene
express
transientexpress
system
provid
protect
influenza
b
viru
challeng
madindarbi
canin
kidney
cell
followup
studi
group
among
sever
other
exhibit
inhibit
influenza
viru
gene
express
shown
pcr
western
blot
analysi
activ
design
dz
shown
depend
mg
dosedepend
mm
manner
rsv
also
target
use
dnazym
seri
dz
design
synthes
silenc
rsv
n
f
gene
one
dz
cleav
rsv
rna
vitro
inhibit
transcript
express
f
viral
gene
reduc
rsv
product
log
protect
rsvinfect
cell
cytopath
effect
use
concentr
addit
wild
rsv
strain
includ
subgroup
b
isol
patient
show
signific
suppress
higher
antirsv
activ
ribavirin
antisens
oligonucleotid
odn
complementari
region
n
rna
treatment
reduc
viral
plaqu
format
lung
rsvinfect
balbc
mice
addit
observ
design
dz
significantli
reduc
viral
mrna
express
allevi
airway
inflamm
reduc
leukocyt
count
bronchoalveolar
lavag
fluid
rsvinfect
mice
show
dosedepend
antivir
effect
observ
effici
antisens
oligonucleotid
mediat
inhibit
gene
express
even
though
level
cytokin
tnfalpha
ifngamma
induc
rsv
infect
unaffect
overal
result
demonstr
use
potenti
therapeut
agent
infect
subgroup
b
rsv
vivo
sarscov
also
target
use
dz
molecul
use
dz
target
untransl
region
utr
highli
conserv
fragment
sarscov
genom
suppress
viral
replic
report
studi
show
efficaci
monodna
enzym
possess
catalyt
motif
vitro
cell
cultur
experi
show
vitro
cleavag
sarscov
rna
substrat
reduc
express
sarscov
utregfp
fusion
rna
mammalian
cell
result
provid
basi
potenti
therapeut
usag
dna
enzym
combat
sar
infect
antisens
oligonucleotid
small
synthet
piec
singlestrand
dna
normal
nucleotid
length
aso
specif
bind
complementari
dnarna
sequenc
watsoncrick
hybrid
bound
target
rna
inhibit
translat
process
either
induc
cleavag
mechan
inhibit
mrna
matur
use
aso
first
report
zamecnik
stephenson
potenti
antivir
therapeut
util
phosphodiest
oligodeoxynucleotid
compos
nucleotid
design
block
rou
sarcoma
viru
replic
sinc
aso
abil
select
inhibit
gene
express
gener
noteworthi
enthusiasm
scientif
medic
commun
specif
breadth
potenti
applic
therapeut
agent
extens
rang
oligonucleotid
analog
becom
avail
past
decad
lead
target
valid
develop
asobas
antivir
agent
whose
efficaci
report
variou
viru
type
vitro
well
vivo
aso
use
empir
modif
dna
rna
need
retain
hybrid
capac
time
increas
stabil
major
alter
introduc
phosphodiest
bond
sugar
ring
backbon
result
three
gener
nucleic
acid
analog
synthesi
aso
oligom
asobas
antivir
agent
specif
design
block
translat
process
either
ribonucleas
h
rnase
h
rnase
p
mediat
cleavag
mrna
ii
steric
nonbond
block
enzym
involv
target
gene
translat
antisens
oligonucleotid
studi
extens
sever
respiratori
virus
promis
result
earliest
studi
use
oligonucleotid
oligo
inhibit
synthesi
virusspecif
protein
includ
influenza
mdck
cell
report
research
observ
modifi
oligo
could
effect
suppress
influenza
viru
product
sinc
sever
aso
synthes
studi
efficaci
influenza
ge
et
al
show
sirna
specif
design
target
conserv
region
viral
genom
potent
inhibit
influenza
viru
product
cell
line
vero
mdck
well
embryon
chicken
egg
wu
et
al
show
vivo
treatment
three
dose
rna
oligonucleotid
confer
signific
protect
infect
chicken
virusinduc
mortal
rate
author
use
mix
rna
oligonucleotid
target
gene
show
signific
reduct
plaqueform
unit
pfu
viral
rna
level
lung
tissu
infect
anim
plaqu
assay
realtim
pcr
analysi
studi
demonstr
rna
oligonucleotid
target
viral
gene
could
potent
inhibit
highli
pathogen
avian
influenza
viru
reproduct
thu
could
potenti
use
prophylaxi
therapi
influenza
viru
infect
human
anoth
studi
gabriel
et
al
use
three
peptideconjug
phosphorodiamid
morpholino
oligom
ppmo
select
target
translat
start
site
region
np
mrna
termin
region
np
viral
rna
prevent
viru
replic
mdck
cell
studi
util
primer
extens
assay
show
treatment
effect
ppmo
markedli
reduc
level
mrna
crna
vrna
anoth
studi
duan
et
al
use
novel
antisens
oligonucleotid
iva
specif
design
termin
conserv
sequenc
found
eight
viral
rna
segment
influenza
viru
monitor
activ
iva
vitro
mdck
cell
vivo
use
mous
model
iva
administ
intranas
mice
daili
day
start
h
postinfect
iva
effect
concentr
rang
inhibit
influenza
viru
induc
cytopath
effect
mdck
cell
iva
also
effect
viru
prevent
death
reduc
weight
loss
reduc
lung
consolid
decreas
lung
viru
titer
lupfer
et
al
show
antisenseppmo
deliv
intranas
rout
abl
inhibit
replic
equin
influenza
viru
mice
compar
control
anoth
studi
group
author
design
antisens
oligonucleotid
common
ncr
segment
iav
genom
inhibit
replic
molecul
demonstr
drastic
reduct
cytopath
effect
caus
end
code
region
nucleotid
prove
notic
inhibitori
similar
relat
studi
antivir
activ
also
observ
doseand
timedepend
howev
independ
cell
substrat
multipl
infect
use
studi
anoth
followup
studi
giannecchini
et
al
investig
whether
analog
inhibitori
son
target
pa
gene
segment
could
identifi
viru
develop
resist
son
author
observ
son
reproduc
end
pa
gene
segment
exert
domin
antivir
activ
sever
influenza
viru
subtyp
mdck
cell
find
suggest
packag
signal
end
vrna
potenti
therapeut
target
design
novel
antiinfluenza
compound
also
antivir
region
could
benefici
owe
less
chang
mutat
viral
gene
recent
rsv
also
target
sever
design
aso
molecul
jairath
et
al
studi
investig
use
oligodeoxyribonucleotid
inhibit
rsv
replic
cell
cultur
human
epitheli
type
cell
infect
rsv
strain
treat
design
oligonucleotid
effect
concentr
valu
obtain
design
antisens
oligonucleotid
target
start
viral
gene
elisa
ptpcr
analys
show
oligonucleotid
inhibit
viru
antigen
product
demonstr
sequenc
specif
deplet
genom
rna
target
target
rna
observ
cleav
specif
antisens
oligonucleotid
bind
site
result
suggest
antisens
oligonucleotid
could
therapeut
valu
rsv
infect
ppmo
abil
readili
enter
cell
interfer
viral
protein
express
steric
hindranc
complementari
rna
lai
et
al
design
two
antisens
ppmo
specif
target
termin
region
translat
startsit
region
rsv
l
mrna
ppmo
demonstr
minim
cytotox
test
antirsv
activ
two
humanairway
cell
line
one
ppmo
reduc
viral
titer
intranas
administr
balbc
mice
rsv
infect
show
reduct
viral
titer
lung
tissu
day
postinfect
reduc
pulmonari
inflamm
day
postinfect
overal
result
show
ppmo
potent
antirsv
activ
potenti
therapeut
regimen
rsv
infect
neuman
et
al
design
specif
ppmo
specif
sequenc
sarscov
strain
genom
ppmo
analyz
capabl
inhibit
infecti
viru
product
investig
determin
function
conserv
vrna
motif
secondari
structur
sever
viru
specif
ppmo
along
randomsequ
control
ppmo
design
show
low
inhibitori
activ
sarscoa
virustarget
ppmo
reduc
cytopatholog
due
viral
infect
reduc
celltocel
spread
reduct
viral
replic
activ
ppmo
found
effect
administ
time
prior
peak
viral
synthesi
exert
sustain
antivir
effect
cultur
medium
studi
demonstr
antivir
effect
vitro
ppmo
design
complementari
aug
translat
start
site
region
murin
coronaviru
replicas
suggest
therapeut
potenti
aso
coronaviru
infect
anoth
studi
ahn
et
al
evalu
antivir
effect
antisens
peptid
nucleic
acid
pna
target
highli
conserv
rna
sequenc
program
ribosom
frameshift
prf
util
eukaryot
rna
virus
cell
transfect
sarscovreplicon
treat
pna
inhibitori
concentr
fuse
cellpenetr
peptid
cpp
show
signific
suppress
replic
sarscov
aptam
nucleotid
long
synthet
singl
strand
nucleic
acid
molecul
dna
rna
design
bind
variou
organ
nonorgan
moleculesrang
singl
atom
wide
rang
protein
figur
aptam
highli
specif
target
molecul
gener
selex
systemat
evolut
ligand
exponenti
enrich
method
last
year
aptam
use
diagnost
tool
treatment
viral
diseas
aptam
nucleotid
long
synthet
singl
strand
nucleic
acid
molecul
dna
rna
design
bind
variou
organ
nonorgan
moleculesrang
singl
atom
wide
rang
protein
figur
aptam
highli
specif
target
molecul
gener
selex
systemat
evolut
ligand
exponenti
enrich
method
last
year
aptam
use
diagnost
tool
treatment
viral
diseas
figur
schemat
represent
action
aptam
aptam
fold
threedimension
structur
function
aptam
recogn
bind
target
molecul
result
stabl
aptamertarget
complex
owe
pandem
natur
diseas
constant
mutat
viru
identif
differ
subtyp
becom
essenti
case
antibodi
use
distinguish
influenza
b
success
probe
distinguish
differ
subtyp
aptam
aptam
common
subunit
viru
use
develop
sensor
influenza
detect
hemagglutinin
ha
influenza
viral
surfac
glycoprotein
respons
fusion
viru
host
cell
case
influenza
least
differ
ha
antigen
identifi
respons
diagnosi
identif
differ
influenza
type
subtyp
sinc
dna
rna
aptam
recombin
hemagglutinin
ha
influenza
viru
b
whole
virus
construct
misono
kumar
use
sprbase
selex
design
select
rna
aptam
show
activ
ha
gopinath
et
al
construct
two
target
rna
aptam
use
differenti
influenza
type
type
b
close
relat
strain
influenza
subtyp
rna
aptam
found
time
specif
influenza
viru
convent
antiha
monoclon
antibodi
subsequ
sever
aptam
construct
detect
influenza
viru
type
well
avian
influenza
viru
aptam
prove
help
diagnos
distinguish
danger
influenza
strain
potenti
high
epidemiolog
risk
wang
li
gener
biosensor
base
quartz
crystal
microbal
qcm
techniqu
modifi
dna
aptam
cross
link
quartz
particl
detect
avian
influenza
viru
specif
similarli
bai
et
al
also
suggest
usag
spr
aptasensor
direct
avian
influenza
later
impedancebas
aptasensor
microfluid
chip
lower
detect
limit
sprbase
aptasensor
sensit
qcm
aptasensor
use
detect
avian
influenza
viru
recent
nguyen
et
al
use
spr
base
sandwich
type
sensor
detect
virus
sensit
dual
aptamerbas
sensor
increas
mani
fold
secondari
aptam
conjug
gold
nanoparticl
chemic
modif
aptam
reduc
select
time
increas
biostabl
vivo
earli
diagnosi
identif
subtyp
help
target
viral
strain
specif
ration
aptam
develop
influenza
therapeut
purpos
mani
aptam
develop
ha
could
prevent
entri
viru
cell
block
owe
pandem
natur
diseas
constant
mutat
viru
identif
differ
subtyp
becom
essenti
case
antibodi
use
distinguish
influenza
b
success
probe
distinguish
differ
subtyp
aptam
aptam
common
subunit
viru
use
develop
sensor
influenza
detect
hemagglutinin
ha
influenza
viral
surfac
glycoprotein
respons
fusion
viru
host
cell
case
influenza
least
differ
ha
antigen
identifi
respons
diagnosi
identif
differ
influenza
type
subtyp
sinc
dna
rna
aptam
recombin
hemagglutinin
ha
influenza
viru
b
whole
virus
construct
misono
kumar
use
sprbase
selex
design
select
rna
aptam
show
activ
ha
gopinath
et
al
construct
two
target
rna
aptam
use
differenti
influenza
type
type
b
close
relat
strain
influenza
subtyp
rna
aptam
found
time
specif
influenza
viru
convent
antiha
monoclon
antibodi
subsequ
sever
aptam
construct
detect
influenza
viru
type
well
avian
influenza
viru
aptam
prove
help
diagnos
distinguish
danger
influenza
strain
potenti
high
epidemiolog
risk
wang
li
gener
biosensor
base
quartz
crystal
microbal
qcm
techniqu
modifi
dna
aptam
cross
link
quartz
particl
detect
avian
influenza
viru
specif
similarli
bai
et
al
also
suggest
usag
spr
aptasensor
direct
avian
influenza
later
impedancebas
aptasensor
microfluid
chip
lower
detect
limit
sprbase
aptasensor
sensit
qcm
aptasensor
use
detect
avian
influenza
viru
recent
nguyen
et
al
use
spr
base
sandwich
type
sensor
detect
virus
sensit
dual
aptamerbas
sensor
increas
mani
fold
secondari
aptam
conjug
gold
nanoparticl
chemic
modif
aptam
reduc
select
time
increas
biostabl
vivo
earli
diagnosi
identif
subtyp
help
target
viral
strain
specif
ration
aptam
develop
influenza
therapeut
purpos
mani
aptam
develop
ha
could
prevent
entri
viru
cell
block
hemagglutinin
activ
could
measur
vitro
use
hemagglutin
inhibit
assay
usag
dna
aptam
show
reduct
viral
infect
administ
concomitantli
viral
infect
mice
model
less
effect
given
prior
infect
musafia
et
al
use
modifi
time
potent
antivir
activ
anim
model
aptam
mani
aptam
target
subunit
import
viral
replic
progress
also
studi
woo
et
al
success
studi
dna
aptam
subunit
particular
aptam
maintain
cell
viabil
induc
product
inhibit
viral
replic
later
aptam
subunit
polymeras
complex
influenza
viru
pa
also
studi
final
aptam
inhibitori
concentr
around
nm
identifi
exhibit
crossprotect
infect
influenza
virus
aptam
target
host
cell
factor
import
viral
replic
also
studi
aptam
inhibit
viral
proteinhost
translat
factor
interact
use
influenza
similarli
use
specif
rigi
aptam
effici
block
replic
influenza
virus
infect
cell
immun
respons
case
yet
anoth
respiratori
viru
sar
nucleocapsid
n
protein
one
abund
protein
target
choic
develop
aptam
ahn
et
al
develop
nanoarray
aptam
chip
rna
aptam
profici
detect
sar
nucleocapsid
protein
concentr
low
pgml
likewis
ssdna
aptam
profici
detect
n
protein
western
blot
rna
aptam
use
target
nonstructur
protein
jang
et
al
inhibit
viral
enzym
activ
dosedepend
manner
nm
yet
anoth
studi
show
dna
aptam
nonstructur
protein
inhibit
helicas
activ
protein
requir
sar
viral
replic
recent
studi
rsv
demonstr
aptam
select
base
ration
design
selex
protocol
whole
viru
specif
aptam
potenti
util
detect
respiratori
syncyti
viru
rna
interfer
mediat
tool
like
shrna
ribozym
dnazym
emerg
import
technolog
studi
gene
function
also
therapeut
purpos
manag
viral
infect
restrict
growth
cancer
cell
biggest
hurdl
use
tool
vivo
deliveri
target
cell
major
challeng
vivo
deliveri
nucleic
acid
includ
immunogen
enzymat
digest
bodi
fluid
phagocytosi
immun
cell
renal
clearanc
moreov
highli
charg
natur
nucleic
acid
allow
cross
cell
membran
free
diffus
intracellular
challeng
deliveri
molecul
includ
endosom
lysosom
escap
cell
cytoplasm
sever
strategi
develop
effici
vivo
deliveri
nucleic
acid
includ
use
viral
well
nonvir
vector
deliveri
vehicl
refer
respiratori
virus
numer
studi
report
nonvir
vector
mediat
vivo
deliveri
sirna
ribozym
target
respiratori
viru
genom
cation
system
like
liposom
polym
success
use
system
administr
sirna
molecul
liposom
vector
posit
charg
effici
form
complex
neg
charg
effector
nucleic
acid
one
side
interact
neg
charg
cell
membran
side
size
vector
also
need
kept
nm
prevent
renal
clearanc
system
administr
polym
polyethyleneimin
pei
could
use
carrier
shrna
target
mrna
encod
pa
protein
influenza
viru
observ
shrna
clone
puro
plasmid
vector
prophylact
effect
mice
infect
deliv
shrnajetpei
complex
intratrach
rout
howev
complex
could
show
therapeut
efficaci
anoth
studi
done
sirna
design
gene
encod
phosphoprotein
rsv
shown
sirna
deliv
intranas
rout
prior
infect
either
nake
complex
transfect
reagent
viz
transittko
reagent
could
significantli
reduc
viral
titer
diseas
outcom
mice
howev
effect
sirna
low
deliv
viru
infect
alnylam
pharmaceut
translat
result
studi
done
bitko
et
al
human
trial
evalu
antivir
activ
sirna
name
cross
phase
clinic
trial
found
safe
deliv
healthi
human
individu
nasal
spray
aerosol
sever
report
show
efficaci
intranas
administr
sirna
complex
transfect
reagent
reduc
viral
titer
lung
infect
mice
reliev
symptom
howev
administr
sirna
complex
polyethyleneimin
transfect
reagent
like
lipofectamin
intraven
rout
also
shown
exert
inhibitori
effect
viru
replic
lung
treat
mice
lead
inhibit
lung
viru
titer
studi
done
tompkin
et
al
direct
intraven
inject
sirnaoligofectamin
pb
aid
effect
intranas
inocul
sirna
complex
target
nucleoprotein
acid
polymeras
gene
thu
reduc
pathogen
highli
virul
influenza
viru
strain
though
pei
transfect
reagent
shown
effect
carrier
rnai
tool
mice
model
feasibl
clinic
use
proinflammatori
effect
li
et
al
demonstr
sirna
complex
carrier
like
solut
infasurf
solut
safe
clinic
use
intratrach
administr
solut
complex
target
spike
code
gene
region
sar
coronaviru
scv
genom
show
effici
inhibit
scv
replic
suppress
sar
like
symptom
monkey
model
apart
abovement
polym
lipidbas
deliveri
shrna
therapeut
rna
molecul
also
deliv
intranas
rout
complex
chitosan
nanoparticl
studi
done
chitosan
nanoparticl
shown
intranas
inocul
chitosan
complex
plasmid
encod
shrna
target
gene
rsv
could
reduc
rsv
infect
lung
patholog
rat
model
complex
also
success
modul
immun
respons
rsv
infect
role
ribozym
therapeut
tool
shown
motard
et
al
design
sofahdvrz
target
mrna
except
hemagglutinin
neuraminidas
gene
influenza
viru
ribozym
target
conserv
region
mrna
correspond
nucleoprotein
nonstructur
gene
influenza
viru
found
inhibit
viru
replic
lung
treat
mice
deliv
intranas
complex
vivojetpeitm
although
extent
reduct
viral
titer
lung
infect
mice
low
ribozym
could
significantli
affect
clinic
outcom
infect
mice
year
anoth
studi
reveal
approach
manag
respiratori
syncyti
viru
rsv
infect
use
ribozym
ribozym
design
l
gene
mrna
rsv
express
via
induc
rsv
minigenom
replicon
system
gener
pseudoviru
particl
defect
rsv
particl
express
therapeut
ribozym
minigenom
system
could
induc
actual
rsv
infect
potenti
inhibit
viru
replic
deliv
intranas
via
pseudoviru
particl
deliveri
vehicl
viral
vector
deliveri
rnai
tool
respiratori
virus
rel
less
discuss
baculoviru
one
vector
insect
viru
vector
known
safeti
high
packag
capac
vector
consid
safe
recombin
baculoviru
replic
incompet
mammalian
cell
produc
immunogen
viral
protein
report
recombin
baculoviru
vector
could
exhibit
transient
effect
express
shrna
target
influenza
b
viru
vitro
condit
durat
express
could
increas
insert
epsteinbarr
viru
sequenc
vector
use
vector
vivo
express
rnai
tool
need
examin
although
rnai
receiv
signific
attent
basic
appli
research
relat
biolog
system
rnai
associ
immun
stimul
may
pose
hurdl
clinic
applic
possibl
innat
immun
respons
induc
sirnasshrna
deliveri
vehicl
yet
anoth
obstacl
need
address
care
recent
studi
shown
advanc
chemic
modifi
rnai
molecul
design
trigger
less
immun
respons
furthermor
potenti
benefit
immunostimulatori
sirna
benefici
case
viral
infect
antagonist
cancer
review
spite
associ
innat
immun
respons
nucleic
acidbas
strategi
still
hold
lot
import
current
undergo
variou
phase
clinic
trial
shown
effect
virus
also
use
target
nonvir
diseas
tabl
respiratori
virus
global
concern
decad
lead
caus
morbid
mortal
children
adult
virus
show
season
pattern
outbreak
manag
proper
precaut
prevent
measur
initi
time
major
one
influenza
rsv
lead
caus
respiratori
diseas
continu
surveil
system
requir
understand
chang
pattern
year
year
coincid
season
aggrav
scenario
although
sever
studi
focus
techniqu
help
diagnos
viral
infect
short
time
symptomat
treatment
avail
prevent
still
better
cure
vaccin
consid
effect
tool
howev
need
annual
vaccin
formul
highli
mutat
influenza
virus
reason
continu
tri
develop
novel
strategi
combat
frequent
epidem
rsv
success
vaccin
yet
vaccin
candid
clinic
trial
nucleic
acidbas
therapeut
gain
popular
abil
target
gene
inhibit
translat
strategi
like
antisens
technolog
ribozym
dnazym
well
rnaibas
therapeut
greatli
improv
recent
year
new
studi
also
develop
improv
strategi
overcom
issu
relat
instabl
util
variou
type
modif
phosphorothio
ps
dna
ome
prove
stabl
normal
dnarna
oligonucleotid
sever
pathogen
includ
virus
target
util
one
nucleic
acid
base
silenc
strategi
numer
studi
conduct
experiment
anim
model
well
cell
cultur
system
evalu
effici
efficaci
molecul
posttranscript
silenc
crucial
viral
gene
obstruct
protein
translat
inhibit
viral
replic
strategi
alreadi
made
place
clinic
trial
efficaci
nucleic
acidbas
molecul
depend
express
stabil
access
target
site
properli
design
modifi
nucleic
acid
may
signific
inhibitori
effect
relev
target
combin
one
type
therapeut
alway
show
synergist
effect
viru
propag
host
cell
although
discuss
therapeut
nucleic
acid
highli
specif
target
optim
nil
offtarget
effect
henc
side
effect
includ
effect
cellular
metabol
expect
neglig
risk
factor
associ
molecul
deliveri
vehicl
especi
viral
vector
appropri
chosen
relat
risk
minim
avail
literatur
strategi
show
tremend
potenti
howev
develop
molecul
simpl
requir
extens
optim
respect
stabil
mode
deliveri
new
discoveri
antivir
compound
bring
associ
challeng
still
effort
discoveri
essenti
potenti
offer
effect
better
tool
manag
viral
infect
